Alan H. Chen Surgical Associates, PC
Joliet, Illinois, 60435, United States
Location status: Recruiting
Location contact
Alan Chen, MD
PRINCIPAL_INVESTIGATOR
Ashtyn N Janovyak, MS, PA-C
CONTACT
Ashtyn N Janovyak, MS, PA-C
SUB_INVESTIGATOR
NCT Number: NCT06512259
This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Interested in participating?
Request Info18 year and older
Female
Observational
Joliet, Illinois, 60435, United States
Location status: Recruiting
Alan Chen, MD
PRINCIPAL_INVESTIGATOR
Ashtyn N Janovyak, MS, PA-C
CONTACT
Ashtyn N Janovyak, MS, PA-C
SUB_INVESTIGATOR
AlloMend® Acellular Dermal Matrix is a sterile, ready to use, human-derived acellular dermal matrix (ADM) allograft that can be used in a number of reconstructive and other surgical procedures. It is made from donated human full-thickness skin. After the epidermal and hypodermal layers are removed, the tissue is treated by a proprietary cleansing process.
AlloMend® is intended to be used in conjunction with a breast implant or tissue expander to stabilize implant position and minimize implant loss during post-single or double mastectomy, unilateral or bilateral pre-pectoral breast reconstruction in women 18 years of age or older. AlloMend® may be used in either one-stage (direct-to-implant) or two-stage (expander-to-implant) procedures.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must meet the following inclusion criteria to participate in this study:
Exclusion criteria
Patients must not meet any of the following criteria to be considered for this clinical trial:
AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
Time frame: Up to 6- months post-operatively
The primary objective is to obtain descriptive data and surgical intervention and post operative surgical outcome data on AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Time frame: Up to 6- months post-operatively
Secondary Objectives will identify changes in physical function and quality of life as assessed for a period of 6-months post-operatively.
Time frame: Up to 6- months post-operatively
Qualitative data such as return to wound healing, pain, discomfort, physicial deformity, and revision surgeries will also be collected.
Contact information is provided by the study sponsor or research team.
Elizabeth Esterl, DNP, MS, RN
CONTACT
Paige McHenry, MS, ATC, CCRA
CONTACT
AlloSource
Industry
A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.